Skip to main content
ACG 2024 Annual Meetings Posters Main banner
Back
Rate ePoster

Sunday Poster Session

Category: Functional Bowel Disease

P0641 - Irritable Bowel Syndrome With Constipation Poses a Substantial Burden to Patient Overall Health Status and Quality of Life: Results From the IBS in America 2024 Real-World Survey

Sunday, October 27, 2024
3:30 PM – 7:00 PM ET
Location: Exhibit Hall E
Has Audio
Eric Shah, MD1, Johannah Ruddy, 2, Belinda Gist, PhD2, Elizabeth Stremke, PhD, RD2, Laura Williams, PhD2, Baharak Moshiree, MD3
1University of Michigan, Ann Arbor, MI; 2Ardelyx, Inc., Waltham, MA; 3Advocate Health Wake Forest Medical University, Charlotte, NC

Introduction: Irritable bowel syndrome with constipation (IBS-C), characterized by >25% of stools being hard and lumpy and < 25% of stools being mushy or watery, accounts for approximately a third of IBS cases. The IBS In America 2024 survey was conducted to gain insight into the experience of patients (pts) with IBS. This study investigated overall health status and quality of life (QoL) in pts with IBS-C.

Methods: IBS In America 2024 was a 15-minute online survey fielded by Health Union from January 15-April 14, 2024, in US residents aged ≥18 years, covering demographics, comorbidities, QoL/impact, treatments, and health care provider (HCP) interactions. Pts who completed the survey and met the following criteria were invited to participate in an institutional review board–approved extension survey: diagnosed with IBS-C or IBS with alternating diarrhea and constipation by an HCP, currently seeing an HCP to treat IBS, and had ever used an over-the-counter or prescription treatment for IBS. This analysis only includes pts diagnosed with IBS-C who completed the extension survey.

Results: Respondents with IBS-C (N=284) had a mean (range) age of 51 (18-86) years and were predominantly female (92%) and White (87%). More than a third of pts (39%) described their QoL as “poor” or “fair,” which they often attributed to having multiple health conditions. The majority of comorbidities included mental health conditions, chronic pain conditions, metabolic disorders, and other gastrointestinal disorders. Pts reported that in the previous 30 days their physical or mental health had been “not good” for an average of 15 and 11 days, respectively. 90% of pts had “some” or “significant” negative impact of IBS-C on their life, with the majority reporting negative impact on their mental/emotional health (“some,” 54%; “significant,” 25%), sexual health/intimacy (40%; 24%), relationships with friends/family (42%; 14%), and sense of independence (43%; 16%). IBS-C was considered a financial hardship to pts and their families “somewhat,” “quite a bit,” or “very much” in 18%, 14%, and 15% of respondents, respectively. 46% of pts reported satisfaction with social activities as “fair” or “poor,” and 43% described fatigue as “severe” or “very severe.”

Discussion: IBS-C adversely impacts many facets of the pt experience and is associated with substantial disease burden and decreased QoL in all areas, including sexual health, mental and emotional wellbeing, and overall relationships with others.


Disclosures:
Eric Shah: Abbvie – Consultant. Ardelyx – Consultant. Cook – Consultant. Laborie – Consultant. Mahana – Consultant. Mylan – Consultant. Neuraxis – Consultant. Salix – Consultant. Sanofi – Consultant. Takeda – Consultant.
Johannah Ruddy: Ardelyx, Inc. – Employee.
Belinda Gist: Ardelyx, Inc. – Employee.
Elizabeth Stremke: Ardelyx, Inc. – Employee.
Laura Williams: Ardelyx, Inc. – Employee.
Baharak Moshiree: AbbVie – Advisory Committee/Board Member. Allergan – Advisory Committee/Board Member. Alnylam Pharmaceuticals – Advisory Committee/Board Member. Ardelyx – Advisory Committee/Board Member. Atmo Biosciences – Advisory Committee/Board Member, Grant/Research Support. Biora Therapeutics (formerly Progenity) – Advisory Committee/Board Member. CinDome Pharma – Grant/Research Support. CinPhloro Pharma – Grant/Research Support. Restalsis Health – Grant/Research Support. Salix Pharmaceuticals of Bausch Health – Grant/Research Support. Takeda Pharmaceuticals – Grant/Research Support.


Eric Shah, MD1, Johannah Ruddy, 2, Belinda Gist, PhD2, Elizabeth Stremke, PhD, RD2, Laura Williams, PhD2, Baharak Moshiree, MD3. P0641 - Irritable Bowel Syndrome With Constipation Poses a Substantial Burden to Patient Overall Health Status and Quality of Life: Results From the IBS in America 2024 Real-World Survey, ACG 2024 Annual Scientific Meeting Abstracts. Philadelphia, PA: American College of Gastroenterology.